GlassScriptPhysician profile
Mishah Azhar
NPI 1083119028
$1,302.29
in general payments reported to CMS, 2019-2025
18 companies · $532 in 2025
The $532 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $148 · 2023: $411 · 2024: $212 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,154.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $339.80 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $172.17 | 2022-2025 | |
| Abbvie INC. | $134.00 | 2023-2025 | Qulipta, Ubrelvy |
| Exact Sciences Corporation | $89.00 | 2023-2025 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $74.76 | 2024-2025 | Heplisav-B |
| Idorsia Pharmaceuticals US INC | $73.18 | 2023 | Quviviq |
| Lilly USA, LLC | $72.18 | 2023-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $71.52 | 2022-2025 | Arexvy, Shingrix, Bexsero |
| Corium, LLC | $60.19 | 2025 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $49.42 | 2023-2025 | Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $35.64 | 2022-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Cranial Technologies, INC | $22.91 | 2023 | Doc Band |
| Boston Scientific Corporation | $21.08 | 2024 | |
| Alk-Abello, INC | $19.20 | 2025 | Neffy, Odactra, Grastek |
| Amgen INC. | $18.45 | 2025 | Repatha |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $17.09 | 2025 | Senza |
| Ultragenyx Pharmaceutical INC. | $16.33 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.37 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mishah Azhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.